GlassScriptPhysician profile
Jayanthi Srinivasiah
NPI 1437137015
$4,478.67
in general payments reported to CMS, 2019-2025
27 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $22.76 · 2021: $107 · 2022: $1,610 · 2023: $1,230 · 2024: $561 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178 · Consulting Fee: $1,080 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.80 |
| Consulting Fee | $1,080.00 |
| Education | $319.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,642.94 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $1,080.00 | 2023 | Orserdu |
| Janssen Biotech, INC. | $334.37 | 2019-2025 | Erleada, Talvey, Darzalex |
| Daiichi Sankyo INC. | $234.22 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Pfizer INC. | $202.42 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $148.55 | 2023-2025 | |
| Abbvie INC. | $98.73 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $74.99 | 2025 | |
| Astellas Pharma US INC | $63.55 | 2023-2025 | Padcev, Vyloy |
| Tempus Ai, INC | $59.31 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $50.88 | 2024-2025 | Keytruda, Lynparza |
| Adaptive Biotechnologies Corporation | $47.00 | 2024-2025 | Clonoseq |
| Array Biopharma INC | $45.71 | 2024 | Braftovi, Lorbrena, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $43.89 | 2019 | |
| Exelixis INC. | $41.28 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.54 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Beone Medicines USA, INC. | $31.07 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $30.90 | 2024 | Xpovio |
| Tersera Therapeutics LLC | $30.62 | 2025 | Zoladex |
| Pharmaessentia USA Corporation | $26.94 | 2025 | Besremi |
| Celgene Corporation | $25.73 | 2024 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $25.36 | 2023 | Epkinly, Imbruvica |
| Coherus Oncology, INC. | $22.76 | 2020 | |
| Springworks Therapeutics, INC. | $21.76 | 2024 | Ogsiveo |
| Eisai INC. | $21.04 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.78 | 2023 | |
| Lilly USA, LLC | $19.33 | 2025 | Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayanthi Srinivasiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.